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Abstract 79 – Knee cartilage morphology in various species and humans
Species Number Cartilage surface area Cartilage thickness Cartilage volume
Rat 16 6.2±0.9 mm2 0.14±0.12 mm 0.81±0.17 mm3
Rabbit 6 69±4.9 mm2 0.37±0.05 mm 23.5±3.9 mm3
Cat 3 85±9.1 mm2 0.67±0.05 mm 55.8±10.5 mm3
Dog 18 196±18 mm2 0.77±0.04 mm 142±15 mm3
Pig 1 1650 mm2 1.4 mm 2200 mm3
Horse 1 2390 mm2 1.4 mm 3290 mm3
Rhinoceros 1 5460 mm2 1.8 mm 9840 mm3
Human (Women) 45 1050±135 mm2 1.9±0.23 mm 1940±344 mm3
Human (Men) 72 1380±205 mm2 2.2±0.26 mm 2940±622 mm3
with those in a data base of young (18 to 35 years) healthy
humans (45 women, weight 60 ± 7 kg, and 72 men, weight 77
± 11 kg) who had been imaged at 1.5T. Sagittal spoiled gradient
echo sequences with fat suppression or water excitations were
acquired in all knees. The medial tibial cartilage was segmented
by tracing the cartilage surface (AC) and subchondral bone area
(tAB) throughout the entire medial tibia. The size of the cartilage
surface areas (AC), the mean cartilage thickness (ThC) and
the cartilage volume (VC) were computed using Chondrometrics
software (Ainring, Germany).
Results: The size of the cartilage surface areas in the rat (6.2
mm2) was approximately 200x smaller than that in humans (Table
1), whereas that in the rhinoceros was about 4.5 x larger than
than in humans. The variability of cartilage thickness between
the species, however, was substantially less than for cartilage
surface areas. All species (including the rhinoceros: ThC = 1.8
mm) had thinner cartilage than humans (1.9 mm in women and
2.2 mm in men, respectively). The rat displayed the lowest mean
cartialge thickness (0.14 mm) amongst the species investigated.
Conclusions: To our knowledge these are the ﬁrst quantitative
data on the three-dimensional morphology of tibial cartilage in
different species and humans. The data show that the inter-
species differences in cartilage surface areas are much more
prominent than those in cartilage thickness. This is likely due to
the need to keep mechanical stresses (load/area) below a critical
threshold at which the cartilage will undergo damage. These data
can be used to estimate the appropriate dose of intra-articular
medication with potentially beneﬁcial structural or symptomatic
effects on articular cartilage in animal models of OA.
80
THERAPEUTIC EFFECTS OF FIBROBLAST GROWTH
FACTOR-18 IN A RAT MODEL OF ESTABLISHED
OSTEOARTHRITIS
C.H. Ladel1, J.L. Ellsworth2, A.M. Bendele3, A. Gimona4,
S. Riva1, E. Vom Baur4
1Merck Serono Research - RBM, Colleretto Giacosa, Italy;
2ZymoGenetics, Inc, Seatlle, WA; 3Bolder BioPATH, Inc., Bolder,
CO; 4Merck Serono S.A., Geneve, Switzerland
Purpose: FGF18 plays a central role in skeletal growth and
development. In contrast to its described role in the growth
plate, where it negatively regulates chondrocyte proliferation and
differentiation, FGF18 has been shown to have signiﬁcant an-
abolic effects on chondrocytes in other cartilaginous tissues. To
evaluate whether recombinant human FGF18 (rhFGF18) could
facilitate the repair of cartilage damage caused by osteoarthritis
(OA), the efﬁcacy of rhFGF18 was tested in a rat meniscal tear
model of OA.
Methods: In the rat meniscal tear model, a full-thickness cut
in the medial meniscus leads to joint instability and progressive
development of OA characterized by proteoglycan loss, cartilage
ﬁbrillation, chondrocyte death, eventual damage to the subchon-
dral bone, and formation of osteophytes.
rhFGF18, formulated in saline, was administered by intra-
articular injection beginning 21 days after meniscal tear using
three different dose regimens: once per week, twice per week
or three times per week with 0, 0.3, 1, 3 or 10 µg/joint overall
weekly dose. Evaluation was performed at 3 weeks and, further
to an initial evaluation of rhFGF18 in this model, at a 3-week
follow-up period after end of therapy to investigate sustained
cartilage effects of rhFGF18.
Results: Treatment with rhFGF18 induced a dose-dependent
increase in cartilage formation and a statistically signiﬁcant in-
crease in the thickness of the articular surface of the medial tibial
plateau. The increase in cartilage formation induced by rhFGF18
was paralleled by signiﬁcant reductions in multiple degeneration
scores. Anabolic effects were seen in most groups and were
greatest in the joints treated 3x/week but this dosing paradigm
also resulted in excessive inﬂammation and bone resorption.
Weekly dosing with 10 or 3 µg resulted in high therapeutic
efﬁcacy. Animals given 3 or 10 µg rhFGF18 had signiﬁcantly
lower cartilage degeneration width (28 and 37% respectively)
and moreover animals given 10 µg rhFGF18 demonstrated a
27% increase of viable cartilage matrix. After 3 additional weeks
without treatment cartilage degeneration scores of the medial
tibia were signiﬁcantly decreased 38% after treatment with 10
µg rhFGF18 1x/week, which resulted in a signiﬁcant decrease
(31%) of cartilage degeneration in the overall joint. Dose respon-
sive beneﬁt was seen in the signiﬁcant cartilage degeneration
parameter and severe matrix loss, as measured by collagen
degeneration, was improved with the once per week dosing reg-
imen, therefore providing the best balance of beneﬁcial effects
versus lack of detrimental effects.
Conclusions: Overall, these results demonstrate that rhFGF18
can stimulate formation of new cartilage in an animal model
of OA, and suggest that rhFGF18 might have clinical utility for
treatment of this disease. rhFGF18 is currently tested in clinical
trials.
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Purpose: MMP-9, or called gelatinase B, is critical for the re-
cruitment of T cells, macrophages, and synovial ﬁbroblasts in
synovial membrame, which often initiates a cascade of degrada-
tive events through several pro-inﬂammatory cytokines including
interleukin 1 (IL-1) and tissue necrosis factor alpha (TNF-α).
MMP-9 is also important for the formation of growth plate car-
ilage and upregulated in OA and injured joint, but its roles in
cartilage degradation after injury is not clear. The aim of this
study was to establish a murine model to study overload injury
in cartilage without alternating joint kinematics and to test our
hypotheses that load-injury in cartilage alone induces cartilage
degradation in part by chronical joint inﬂammation and that the
